NHS England successfully negotiates access to new drug treatment for children with duchenne muscular dystrophy
Children in England suffering from a rare form of muscular dystrophy should soon be able to access the only drug for their condition after a ground-breaking agreement was reached between NHS England and the manufacturer. NHS England and the manufacturer, PTC Therapeutics, have successfully negotiated a managed access agreement (MAA) for ataluren (brand name Translarna) […]